NK/T细胞白血病/淋巴瘤免疫治疗的研究进展

Progress of immunotherapy for NK/T cell leukemia/lymphoma

NK/T细胞白血病/淋巴瘤是一类起源于T细胞或自然杀伤细胞的恶性肿瘤,发病率低,尚缺乏明确且有效的治疗策略,临床预后不良。近年来靶向疗法在血液系统肿瘤治疗中取得很大进展,包括单克隆抗体和嵌合抗原受体T细胞(CAR⁃T)疗法,其中以CD30、CD7、CD5、CD52、CCR4等为靶抗原治疗NK/T细胞白血病/淋巴瘤的临床研究取得一定疗效,因而备受关注,但其广泛应用仍面临巨大挑战。文章就近年来NK/T细胞白血病/淋巴瘤免疫治疗的进展进行综述。

NK/T cell leukemia/lymphoma is a type of malignancy originating from T cells or natural killer cells with low incidence and poor clinical prognosis.There is still no effective treatment strategy.In recent years,targeted therapy has made great progress in the treatment of hematological malignancies,including monoclonal antibody and chimeric antigen receptor T cells(CAR⁃T),among which CD30,CD7,CD5,CD52,CCR4 and other target antigens are effective in the treatment of NK/T cell leukemia/lymphoma,but its widespread application still faces a great challenge.This article reviews the progress of immunotherapy for NK/T cell leukemia/lymphoma.